Arabic Arabic English English French French German German

Impact of Data Integrity Issues on Pharmacology/Toxicology Studies in ANDAs

Victoria Keck, MS, VMD, Division of Clinical Review, discusses types of studies impacted by data integrity issues, common types of data integrity issues, key collaborations in identifying/investigating these issues, the impact of these issues on the review process, and how to manage the impact of the issues on the review process.
Learn more at:
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training –   
SBIA Listserv –
SBIA 2021 Playlist –
SBIA LinkedIn –  
SBIA Training Resources –  
Twitter –  
Email –  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Bioavailability/Bioequivalence Site Evaluation During the Pandemic

Next Post

Panel Discussion

Related Posts